← Back to patent-cliff list
DUK-CPG-001
Tier C — Watch / tradeDUK-CPG-001
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：TLR9
Indications (approved)：Lymphoma, Myeloid leukaemia, Non-Hodgkin lymphoma, Hodgkin's disease
Regional status
US
Phase II
2016-06-08
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of DUK-CPG-001?
Approved indications include: Lymphoma, Myeloid leukaemia, Non-Hodgkin lymphoma, Hodgkin's disease.
When does the DUK-CPG-001 patent expire?
No public expiry year is available for DUK-CPG-001 yet; this page updates once verified.
How do I get a quote for DUK-CPG-001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-10